1. Home
  2. IROH vs CTMX Comparison

IROH vs CTMX Comparison

Compare IROH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROH
  • CTMX
  • Stock Information
  • Founded
  • IROH 2021
  • CTMX 2008
  • Country
  • IROH United States
  • CTMX United States
  • Employees
  • IROH N/A
  • CTMX N/A
  • Industry
  • IROH
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROH
  • CTMX Health Care
  • Exchange
  • IROH Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • IROH 91.2M
  • CTMX 85.3M
  • IPO Year
  • IROH 2023
  • CTMX 2015
  • Fundamental
  • Price
  • IROH $10.38
  • CTMX $0.84
  • Analyst Decision
  • IROH
  • CTMX Buy
  • Analyst Count
  • IROH 0
  • CTMX 6
  • Target Price
  • IROH N/A
  • CTMX $5.77
  • AVG Volume (30 Days)
  • IROH 44.0K
  • CTMX 847.0K
  • Earning Date
  • IROH 01-01-0001
  • CTMX 03-10-2025
  • Dividend Yield
  • IROH N/A
  • CTMX N/A
  • EPS Growth
  • IROH N/A
  • CTMX N/A
  • EPS
  • IROH 0.20
  • CTMX 0.16
  • Revenue
  • IROH N/A
  • CTMX $126,617,000.00
  • Revenue This Year
  • IROH N/A
  • CTMX $22.55
  • Revenue Next Year
  • IROH N/A
  • CTMX N/A
  • P/E Ratio
  • IROH $53.07
  • CTMX $5.20
  • Revenue Growth
  • IROH N/A
  • CTMX 33.66
  • 52 Week Low
  • IROH $9.97
  • CTMX $0.79
  • 52 Week High
  • IROH $11.11
  • CTMX $5.85
  • Technical
  • Relative Strength Index (RSI)
  • IROH N/A
  • CTMX 45.15
  • Support Level
  • IROH N/A
  • CTMX $0.82
  • Resistance Level
  • IROH N/A
  • CTMX $0.98
  • Average True Range (ATR)
  • IROH 0.00
  • CTMX 0.06
  • MACD
  • IROH 0.00
  • CTMX 0.01
  • Stochastic Oscillator
  • IROH 0.00
  • CTMX 33.58

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: